AGAMREE

USDailyMed:Vamorolone H02AB18(WHO) CA:℞-onlyUS:℞-onlyEU:Rx-only (8S,10S,13S,14S,16R,17R)-17-Hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one 13209-41-1 3035000 DB15114 2299335 8XP29XMB43 D11000 CHEBI:228304 ChEMBL2348780 DTXSID60927527 Interactive image C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C‍‍‍‍‍‍​​​‍​​​​​​3=CC[C@@]2([C@]1(C(=O)CO)O)C)C InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1Key:ZYTXTXAMMDTYDQ-DGEXFFLYSA-N Vamorolone, sold under the brand nameAgamree, is asyntheticcorticosteroid, which is used for the treatment ofDuchenne muscular dystrophy.It is takenby mouth.It is a dual atypicalglucocorticoidandantimineralocorticoid. The most common adverse reactions include cushingoid features, psychiatric disorders, vomiting, increased weight, and vitamin D deficiency. Vamorolone was approved for medical use in the United States in October 2023,and in the European Union in December 2023.